Anti-Mouse IFNAR-1 [Clone MAR1-5A3] — Purified in vivo PLATINUM™ Functional Grade
![Anti-Mouse IFNAR-1 [Clone MAR1-5A3] — Purified in vivo PLATINUM™ Functional Grade, Product Vial— Leinco Prod. No. I-1188](https://www.leinco.com/wp-content/uploads/2019/04/I-1188-IFNAR-MAR1-5A3-Vial-Parent-500x500.jpg)
Anti-Mouse IFNAR-1 [Clone MAR1-5A3] — Purified in vivo PLATINUM™ Functional Grade
Product No.: I-1188
Clone MAR1-5A3 Target IFNAR1 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD118, Ifar, Ifnar, Ifrc, INF-a receptor, Interferon-α/β receptor α chain Isotype Mouse IgG1 Applications B , ELISA , FC , in vivo , IP , WB |
Data
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Plasmid DNA encoding murine IFNAR1 extracellular domain Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2830518 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for clone MAR1-5A3 antibody for staining cells in flow cytometry is ≤ 2.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Additional Applications Reported In Literature ? B Clone MAR1-5A3 has a short half-life due to the rapid recycling of cells that express the IFNAR1 receptor. In order to block function In vivo, continual blocking of all compartments is necessary. Therefore, a large loading dose is necessary to saturate all In vivo binding sites and should be maintained to ensure binding site saturation. For In vivo blocking studies, a loading dose of 2.5 mg/mouse, followed by a weekly dose of 0.5 mg/mouse is recommended. The half-life following a 2.5 mg loading dose is approximately 5 days. However, if you fail to saturate the binding sites by injecting a low dose of 250 μg, for example, the half life is only 1.5 days. WB IP ELISA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone MAR1-5A3 recognizes an epitope on mouse IFNAR1. Background IFNAR1 is a type I membrane protein, that in conjunction with IFNAR2, makes up the heterodimeric receptor that binds all type I IFNs, which includes IFN α and β. Binding and activation of the receptor stimulates Janus protein kinases, which leads to the phosphorylation of several other proteins, namely STAT1 and STAT2. IFNAR1 has also been shown to interact with PRMT1 and Tyrosine kinase 2. Type I IFNs are a family of cytokines that have been shown to promote anti-viral, anti-microbial, anti-tumor and autoimmune responses In vivo. Antigen Distribution IFNAR1 and IFNAR2 are coexpressed on nearly all cells. Ligand/Receptor IFN-α/β NCBI Gene Bank ID UniProt.org Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. The MAR1-5A3 clone is a monoclonal antibody specifically designed for blocking Type I interferon receptor signaling in mouse studies. This antibody targets the IFNAR-1 (interferon alpha/beta receptor subunit 1) and serves as a powerful research tool for investigating the role of Type I interferons in various biological processes. Mechanism of ActionThe MAR1-5A3 antibody works by binding to the extracellular domain of the IFNAR1 subunit of the mouse interferon alpha/beta receptor. This binding blocks the interaction between Type I interferons (IFN-?/?) and their receptor complex, effectively preventing the downstream cellular responses that would normally be triggered by interferon signaling. Importantly, this antibody is non-depleting, meaning it blocks receptor function without actually depleting the cells that express IFNAR1. Dosing ProtocolsThe dosing strategy for MAR1-5A3 requires careful consideration due to the rapid recycling of IFNAR1-expressing cells. For effective in vivo blocking studies, researchers typically use a loading dose of 2.5 mg per mouse, followed by weekly maintenance doses of 0.5 mg per mouse. Alternative protocols involve administering 200 µg every three days, five times to achieve sustained blockade. The high initial dose is necessary to saturate all binding sites throughout the body, while maintenance dosing ensures continued receptor blockade. Research ApplicationsMAR1-5A3 has proven valuable for studying various Type I interferon-mediated responses, including:
Technical ConsiderationsThe antibody has a relatively short half-life due to the rapid turnover of IFNAR1-expressing cells, which necessitates frequent dosing to maintain effective blockade. Researchers must ensure continual blocking of all compartments to achieve complete inhibition of interferon signaling throughout the study period. The antibody effectively abrogates the induction of interferon-stimulated genes (ISGs) in vivo, providing a reliable method for studying interferon-independent pathways. This clone has become a standard tool in immunology research, with over 150 citations for one commercial preparation alone, demonstrating its widespread utility in understanding Type I interferon biology in mouse models. The correct storage temperature for sterile packaged clone MAR1-5A3 (anti-mouse IFNAR-1 monoclonal antibody) is between 2?°C and 8?°C; the solution should be stored undiluted and protected from prolonged exposure to light, and must not be frozen. For most routine laboratory use (including conjugated and unconjugated forms), storage at 2–8?°C is standard. This temperature condition is confirmed by several reputable suppliers for both PE-conjugated and purified versions. Long-term storage at colder temperatures (such as ? –70?°C) may be recommended by some suppliers if aliquoted and sterile, but for general use and to preserve antibody integrity, refrigeration (2–8?°C) is the primary guideline. Key storage considerations:
Common Antibodies and Proteins Used Alongside MAR1-5A3 in the LiteratureMAR1-5A3 is a well-characterized monoclonal antibody targeting mouse IFNAR-1 (Interferon-alpha/beta receptor subunit 1), widely used to block Type I interferon (IFN-?/?) signaling in vivo and in vitro. In experimental settings, it is often used in combination with other antibodies or proteins to dissect the roles of specific cytokines, receptors, or as controls. Frequently Paired Antibodies and Proteins
Typical Experimental ContextsThese antibodies are often used together in infection models (e.g., West Nile Virus) to dissect the relative contributions of IFN-? and IFN-? to host defense and immunopathology. The experimental design typically involves administering MAR1-5A3 alone or in combination with TIF-3C5 and/or HD?-4A7, with appropriate isotype controls, to assess survival, viral load, and immune cell activation. Summary Table
Key Points
This combination of reagents allows precise manipulation and analysis of Type I interferon signaling pathways in murine models. Clone MAR1-5A3 has been extensively studied in scientific literature as a powerful tool for investigating type I interferon (IFN-I) signaling, with key findings spanning multiple areas of immunology and virology research. Mechanism and FunctionMAR1-5A3 is a monoclonal antibody that specifically blocks mouse IFNAR-1 (IFN alpha/beta receptor subunit 1), effectively inhibiting type I interferon receptor signaling both in vitro and in vivo. This antibody was produced through genetic immunization of IFNAR1 knockout mice with a plasmid encoding the extracellular domain of murine IFNAR1. The blocking mechanism disrupts the heterodimeric receptor complex formed by IFNAR-1 and IFNAR-2, which is normally responsible for binding all type I interferons including IFN-? and IFN-?. Viral Infection ModelsFlavivirus Research Applications One of the most significant applications of MAR1-5A3 has been in developing mouse models for flavivirus infections. Researchers have successfully used transient IFNAR1 blockade to enhance viral replication of various flaviviruses that typically replicate poorly in wild-type mice. For West Nile Virus (WNV), MAR1-5A3 treatment enhanced viral replication and shortened the mean time to death in an age- and dose-dependent manner. Zika Virus Studies MAR1-5A3 has proven particularly valuable for Zika virus research. For the Asian lineage ZIKV strain H/PF/2013, which showed limited replication in wild-type mice, pre-treatment with MAR1-5A3 strongly enhanced viremia. More dramatically, the African lineage ZIKV strain Dakar 41525 replicated to high titers in the brains of MAR1-5A3-treated mice and caused lethal disease in nearly half of the subjects. Dengue Virus Model Development Recent research has focused on using MAR1-5A3 to create tractable dengue virus infection models. Studies showed that transient blockade of type I IFN signaling promoted replication of the D2Y89P dengue strain in adult wild-type mice, though it did not consistently lead to virus-induced disease development. The antibody's reported half-life of 5.2 days in wild-type mice makes it suitable for short-term experimental interventions. Tissue Repair and RecoveryBeyond viral research, MAR1-5A3 has revealed important insights into tissue repair mechanisms. Studies have demonstrated that IFN signaling interferes with lung repair during influenza recovery in mice, with IFN-? driving these effects most potently. This finding suggests that while type I interferons are crucial for initial antiviral responses, their continued presence may impede tissue healing processes. Persistent Viral Infection DynamicsResearch using MAR1-5A3 has shown that IFNAR1 signaling in natural killer (NK) cells promotes persistent virus infection. This counterintuitive finding suggests that while type I interferon signaling is generally considered antiviral, it can paradoxically contribute to viral persistence under certain circumstances, particularly through its effects on NK cell function. Technical Considerations and LimitationsThe effectiveness of MAR1-5A3 varies significantly depending on multiple experimental factors. These include strain-specific virulence determinants, viral passage history, dose, inoculation route, and mouse age. The antibody reportedly does not cross the blood-brain barrier efficiently, which influences the neurovirulence patterns observed in different virus strains. Additionally, researchers have noted that higher antibody doses may be required to saturate IFNAR1 in adult versus young mice. Research Applications and Future DirectionsMAR1-5A3 has become an essential tool for high-throughput evaluation of next-generation vaccines and antiviral intervention strategies. Its ability to create more permissive infection models while maintaining other aspects of immune function makes it particularly valuable for pre-clinical testing. The antibody's widespread use is evidenced by over 150 product citations in the scientific literature, demonstrating its importance as a research reagent across multiple fields of study. References & Citations1.) Beaver, Jacob T. et al. (2020) Human Vaccines & Immunotherapeutics 16:9, 2092-2108 Article Link 2.) Theofilopoulos, AN. et al. (2012) J Immunol. 189: 000–000. Article Link 3.) Oldstone, Michael B. A. et al. (2017) Proc Natl Acad Sci U S A. 114(14): 3708–3713. PubMed 4.) Schreiber, RD et al. (2015) PLoS One.10(5):e0128636PubMed 5.) Shin, Haina et al. (2018) J Virol. 92(7): e00038-18. PubMed 6.) Crack, Peter J. et al. (2016) eNeuro 10.1523/ENEURO.0128-15.2016 Article Link 7.) Sheehan, K. C. F. et al. (2006) JICR 26(11):804 8.) Dunn, G. P. et al. (2005) Nat. Immunol. 6(7):722 9.) Fenner, J. E. et al. (2006) Nat. Immunol. 7(1):33 10.) Biron, C. A. et al. (2007) J Exp Med. 204(10): 2383 11.) Sharma S. et al. (2020) Human Vaccines & Immunotherapeutics 16(9):2196-2203 Journal Link 12.) Cliffe, A. et al. (2021) EMBO Reports 22(9):e52547 Journal Link Technical ProtocolsB      Certificate of Analysis |
Formats Available
Prod No. | Description |
|---|---|
I-400 | |
I-1014 | |
I-1018 | |
I-402 | |
I-401 | |
I-1033 | |
I-1032 | |
I-1188 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
